The United States Patent and Trademark Office (USPTO) has published a new patent application, US20260085125A1, concerning apelin receptor binding polypeptides and associated methods. The application, filed on November 25, 2025, describes antibodies and polypeptides designed to specifically bind to the apelin receptor (APJ), along with compositions, nucleic acids, expression vectors, host cells, and methods for treating subjects using these antibodies.

This publication represents a new patent application and does not impose immediate regulatory obligations. However, companies involved in the development of therapeutics targeting the apelin receptor should be aware of this intellectual property filing. Further review of the full patent application may be necessary for entities operating in this specific area of biotechnology and drug development.